ProCE Banner Activity

Pooled Post Hoc Analysis of Safety Outcomes From Phase III CARDINAL and CADENZA Trials of Sutimlimab in Cold Agglutinin Disease

Conference Coverage

In this pooled post hoc analysis of patients with cold agglutinin disease enrolled on the phase III CARDINAL and CADENZA trials, sutimlimab was well tolerated, with few patients developing a serious adverse event possibly related to treatment.

Released: December 14, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.